Primary colon cancer: ESMO clinical practice guidelines for diagnosis, adjuvant treatment and follow-up

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Labianca, R ^a   Nordlinger, B ^b   Beretta, G D ^c   Brouquet, A ^b   Cervantes, A ^d  

^a OSPEDALI RIUNITI   (Italy)

^b HÔPITAL AMBROISE PARÉ   (France)

^c Sant'Orsola Fatebenefratelli Hospital   (Italy)

^d UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; ESTROGEN; FLUOROPYRIMIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PROGESTERONE;

ADJUVANT THERAPY; ALOPECIA; ARTICLE; BARIUM ENEMA; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER INCIDENCE; CANCER INVASION; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CHEMOTHERAPY INDUCED EMESIS; CIGARETTE SMOKING; CLINICAL TRIAL; COLON ADENOMA; COLON CANCER; COLON POLYPOSIS; COLON RESECTION; COLON SURGERY; COLONOSCOPY; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC COLONOGRAPHY; DIARRHEA; DIET THERAPY; DIETARY INTAKE; DISEASE FREE SURVIVAL; DRUG INFUSION; ENDOSCOPIC POLYPECTOMY; ENTERITIS; EVENT FREE SURVIVAL; FOLLOW UP; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HAND FOOT SYNDROME; HUMAN; ILEORECTAL ANASTOMOSIS; LAPAROSCOPIC SURGERY; METABOLIC SYNDROME X; MONOTHERAPY; NEUROTOXICITY; OCCULT BLOOD TEST; PRACTICE GUIDELINE; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSOCIAL CARE; RECURRENT CANCER; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SENSORY NEUROPATHY; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOEMBRYONIC ANTIGEN; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; COLONOSCOPY; EARLY DETECTION OF CANCER; EUROPE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; META-ANALYSIS AS TOPIC; NEOPLASM STAGING; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77954320936     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq168     Document Type: Article

References (62)

1. Parkin DM, Whelan SL, Ferlay J. Cancer incidence in five continents. Lyon: International Agency for Research on CancerVol. VIII. IARC Scientific Publications No. 155, 2002.
2. Berrino F, De Angelis R, Sant M et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007; 8: 773-783.
3. WCRF-AICR. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington DC: AICR 2007.
4. Asano TK, McLeod RS. Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: a systematic review. Dis Colon Rectum 2004; 47: 665-673.
5. von Roon AC, Reese G, Teare J et al. The risk of cancer in patients with Crohn's disease. Dis Colon Rectum 2007; 50: 839-855.
6. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-535.
7. Ahmed RL, Schmitz KH, Anderson KE et al. The metabolic syndrome and risk of incident colorectal cancer. Cancer 2006; 107: 28-36.
8. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004; 350: 991-1004.
9. Stewart BW, Kleihus P (eds): World Cancer Report. Lyon: IARC Press 2003.
10. Aarnio M, Sankila R, Pukkala E et al. Cancer risk in mutation carriers of DNAmismatch-repair genes. Int J Cancer 1999; 81: 214-218.
11. Cochrane Database Syst Rev. 2007 Jan 24; (1): CD001216 Screening for colorectal cancer using the faecal occult blood test, Haemoccult.
12. Accp. Advisory Committee on Cancer Prevention. Recommendations on cancer screening in the European union. Eur J Cancer 2000; 36: 1473-1478.
13. Winawer S, Fletcher R, Rex D et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 2003; 124: 544-560.
14. Mainenti PP, Romano M, Imbriaco M et al. Added value of CT colonography after a positive conventional colonoscopy: impact on treatment strategy. Abdom Imaging 2005; 30: 42-47.
15. Copel L, Sosna J, Kruskal JB et al. CT colonography in 546 patients with incomplete colonoscopy. Radiology 2007; 244: 471-478.
16. Furukawa H, Ikuma H, Seki A et al. Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer. Gut 2006; 55: 1007-1011.
17. González-Moreno S, González-Bayón L, Ortega-Pérez G et al. Imaging of peritoneal carcinomatosis. Cancer 2009; 15: 184-189.
18. Van Cutsem E, Dicato M, Wils J et al. Adjuvant treatment of colorectal cancer (Current expert opinion derived from the Third International Conference on Perspectives in Colorectal Cancer, Dublin, 2001). Eur J Cancer 2002; 38: 1429-1431.
19. Busch OR, Hop WC, Hoynck VPM et al. Blood transfusions and prognosis in colorectal cancer. N Engl J Med 1993; 328: 1372-1376.
20. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-257.
21. Sargent D, Marsoni S, Thibodeau SN et al. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC). A pooled molecular reanalysis of randomized chemotherapy trials. Proc ASCO 2008; 26: 4008.
22. Tejpar S et al. ASCO 2009.
23. Bertagnolli MM, Niedzwiecki D, Compton CC et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009; 27: 1814-1821.
24. Sargent D, Goldberg RM, Jacobson SD et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl Med 2001; 345: 1091-1097.
25. Cready Mc et al. ASCO 2009.
26. Weiser MR, Landmann RG, Kattan MW et al. Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol 2008; 26: 380-385.
27. Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 2004; 350: 2050-2059.
28. Hewett PJ, Allardyce RA, Bagshaw PF et al. Short-term outcomes of the Australasian randomized clinical study comparing laparoscopic and conventional open surgical treatments for colon cancer: the ALCCaS trial. Ann Surg 2008; 248: 728-738.
29. Single-stage treatment for malignant left-sided colonic obstruction: a prospective randomized clinical trial comparing subtotal colectomy with segmental resection following intraoperative irrigation. The SCOTIA Study Group. Subtotal Colectomy versus On-table Irrigation and Anastomosis. Br J Surg 1995; 82: 1622-1627.
30. Ng KC, Law WL, Lee YM et al. Self-expanding metallic stent as a bridge to surgery versus emergency resection for obstructing left-sided colorectal cancer: a case-matched study. J Gastrointest Surg 2006; 10: 798-803.
31. Andrè T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
32. Andrè T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116.
33. Wolmark N, Wieand HS, Kuebler JP et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. Proc ASCO 2005; 23: 16.
34. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-2704.
35. Schmoll HJ, Cartwright T, Tabernero J et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007; 25: 102-109.
36. Schmoll HJ....XELOXA...Proc ESMO 2009.
37. Saltz L, Niedzwiecki D, Hollis D et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). Proc ASCO 2004; 22: 245.
38. Van Cutsem E, Labianca R, Bodoky G et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC 3. J Clin Oncol 2009; 27: 3117-3125.
39. Ychou M, Raoul JL, Douillard JY et al. A phase III randomized trial of LV5FU2 + irinotecan versus 5LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD 9802). Ann Oncol 2009; 20: 674-680.
40. Wolmark N et al. ASCO 2009.
41. Schoemaker D, Black R, Giles L et al. Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. Gastroenterology 1998; 114: 7-14.
42. Makela JT, Laitinen SO, Kairaluoma MI. Five-year follow up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Arch Surg 1995; 130: 1062-1067.
43. Ohlsson B, Breland U, Ekberg H et al. Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up. Dis Colon Rectum 1995; 38: 619-626.
44. Kjeldsen BJ, Kronborg O, Fenger C et al. A prospective randomized study of follow-up after radical surgery for colorectal cancer. Br J Surg 1997; 84: 666-669.
45. Bruinvels DJ, Stiggelbout AM, Kievit J et al. Followup of patients with colorectal cancer. A metaanalysis. Ann Surg 1994; 219: 174-182.
46. Rosen M, Chan L, Beart RW et al. Followup of colorectal cancer: a metaanalysis. Dis Colon Rectum 1998; 41: 1116-1126.
47. Renehan AG, Egger M, Saunders MP et al. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and metaanalysis of randomised trials. BMJ 2002; 324: 813.
48. Figueredo A, Rumble RB, Maroun J et al. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer 2003; 3: 26.
49. Jeffery GM, Hickey BE, Hider P. Follow-up strategies for patients treated for nonmetastatic colorectal cancer. Cochrane Database Syst Rev 2007 CD002200.
50. Tjandra JJ, Chan MKY. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum 2007; 50: 1783-1799.
51. Renehan AG, Egger M, Saunders MP et al. Mechanisms of improved survival from intensive follow-up in colorectal cancer: a hypothesis. Br J Cancer 2005; 92: 430-433.
52. Gan S, Wilson K, Hollington P. Surveillance of patients following surgery with curative intent for colorectal cancer. World J Gastroenterol 2007; 13: 3816-3823.
53. Chau I, Allen MJ, Cunningham D et al. The value of routine serum carcinoembryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol 2004; 22: 1420-1429.
54. Rex DK, Kahi CJ, Levin B et al. Guidelines for colonoscopy surveillance after cancer resection: A consensus update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2006; 130: 1865-1871.
55. Sargent DJ, Patiyil S, Yothers G et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 2007; 29: 4569-4574.
56. Desch C, Benson A, Somerfield M et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology Practice Guideline. J Clin Oncol 2005; 23: 8512-8519.
57. Van Cutsem E, Oliveira J. Primary colon cancer: ESMO Clinical Recommendations for diagnosis, adjuvant treatment and follow up. Ann Oncol 2009; 20 (Suppl 4): iv49-iv50.
58. Tsikitis VL, Malireddy K, Gree EA et al. Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial. J Clin Oncol 2009; 27: 3671-3676.
59. Tejpar S, Bosman F, Delorenzi M et al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial). Proc ASCO 2009. J Clin Oncol 2009 27 (15 suppl): 27 Abstr 4001.
60. Meyerhardt JA, Jackson McCleary N, Niedzwiecki D. Impact of age and comorbidities on treatment effect, tolerance, and toxicity in metastatic colorectal cancer (mCRC) patients treated on CALGB 80203. Proc ASCO 2009. J Clin Oncol 2009; 27 (15 suppl): Abstr 4038.
61. Haller D, Tabernero J, Maroun J et al. First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study). Proc ESMO. European Journal of Cancer Supplements2009 2009; 7(3): 4 (Abstr 5LBA).
62. Wolmark N, Yothers G, O'Connell MJ et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. Proc ASCO 2009. J Clin Oncol 2009; 27 (15 suppl): Abstr LBA4.